Alcobra Ltd. (NASDAQ:ADHD) was upgraded by research analysts at WBB Securities from a “hold” rating to a “buy” rating in a report issued on Monday. The brokerage currently has a $2.00 price objective on the biotechnology company’s stock. WBB Securities’ target price points to a potential upside of 90.48% from the company’s previous close.

A number of other equities research analysts have also issued reports on ADHD. Jefferies Group LLC reiterated a “hold” rating and issued a $1.25 price target on shares of Alcobra in a research note on Monday, June 12th. Zacks Investment Research upgraded Alcobra from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, July 18th. Finally, Roth Capital lowered Alcobra from a “buy” rating to a “neutral” rating and cut their price target for the stock from $4.00 to $1.00 in a research note on Friday, September 29th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $1.56.

Alcobra (NASDAQ ADHD) traded up 2.86% during midday trading on Monday, reaching $1.08. The company had a trading volume of 608,909 shares. The company’s market capitalization is $29.77 million. Alcobra has a 52 week low of $0.83 and a 52 week high of $2.70. The firm has a 50-day moving average price of $1.05 and a 200-day moving average price of $1.11.

Alcobra (NASDAQ:ADHD) last issued its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.02. Analysts expect that Alcobra will post ($0.50) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/10/09/alcobra-ltd-adhd-lifted-to-speculative-buy-at-wbb-securities.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Worth Venture Partners LLC boosted its holdings in shares of Alcobra by 35.6% during the 2nd quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock valued at $305,000 after purchasing an additional 71,465 shares during the last quarter. Royce & Associates LP boosted its holdings in shares of Alcobra by 15.5% during the 1st quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock valued at $849,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of Alcobra by 7,251.0% during the 1st quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 101,514 shares during the last quarter. 29.68% of the stock is owned by institutional investors and hedge funds.

About Alcobra

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Analyst Recommendations for Alcobra (NASDAQ:ADHD)

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.